Riboswitches were discovered in 2002 by Ron Breaker at Yale as RNA-based intracellular sensors of vitamin derivatives. During the last decade, riboswitches have been identified that bind a range of small biomolecules including nucleotides, amino acids, and ions. Riboswitches exert regulatory control of transcription, translation, splicing, and RNA stability. BellBrook scientists used a riboswitch that
BellBrook Labs has been awarded an $860,000 Phase II SBIR grant from the National Institutes of General Medical Sciences to develop an innovative methyltransferase assay for epigenetic drug discovery.  The company’s scientists engineered a fluorescent light switch into a bacterial metabolite sensor to leap-frog the limitations of conventional reagents. Madison, WI – August 31, 2016
Discovery on Target 2016 September 19-22 Westin Boston Waterfront Boston, MA Exhibition Visit Booth #24 to: Discuss BellBrook’s current HTS assays. Share your thoughts on the future of drug discovery. Learn about upcoming AptaFluor™ HTS assays! Presentations/Talks AptaFluor™ Methyltransferase Assay: A Homogenous, Universal HMT Assay Based on a Microbial Riboswitch Tuesday, September 20th – 3:15PM Poster
There are many phosphodiesterase assay kits currently on the market. Comparing the various assays allows pharmaceutical companies to determine for themselves the advantages of using a Transcreener biochemical assay. At BellBrook Labs, located in Madison, WI, we focus on developing HTS assays which can be used to streamline and enhance the drug discovery process. For

Fighting Infection’s Ghost

Aicardi–Goutières syndrome (AGS) is a rare and brutal genetic condition. Most infants born with the syndrome are asymptomatic at birth, but about 1 in 5 have enlarged spleen and liver, elevated liver enzymes in the blood, decreased platelet level, and abnormal neurological responses. Over the first year of life, things get much worse: episodes of
Viral trespassers leave traces of themselves as they overtake cells. The presence of hallmark viral molecules—called PAMPs, for pathogen-associated molecular patterns—allows innate immune system sensors to detect the trail of viral substances as effectively as Sherlock Holmes in miniature. Some of these sensors, or pattern recognition receptors (PRRs), nose out viral DNA and RNA. When
See our latest publication, “Development and Validation of a Universal High-Throughput UDP-Glycosyltransferase Assay with a Time-Resolved FRET Signal” in ASSAY and Drug Development Technologies BellBrook Labs scientist Tom Zielinski collaborated with investigators in Mel Reichman and Preston Donover of the Lankenau Institute for Medical Research to develop a robust assay method for screening and profiling
The methyltransferase SMYD3 is overexpressed in several tumor types, and its overexpression correlates with aggressiveness in breast carcinoma.    Its epigenetic role has been investigated extensively: SMYD3 methylates histone H4 at K5, stimulating expression of critical oncogenic proteins that drive cell proliferation, invasion and metastasis.  However, it has recently been discovered that SMYD3 also methylates non-histone

Unraveling RhoGDIα Regulation

Rho proteins are small, monomeric GTPases in the Ras superfamily that control cell shape and motility by regulating cytoskeletal dynamics. They cycle between a GDP-bound inactive state and a GTP-bound active state. When in the active state, Rho proteins bind to effectors at the plasma membrane, which regulate cellular processes such as cell architecture, intracellular
Drugs targeting cyclin-dependent kinases (CDKs) have been a hot topic in the development of cancer treatments. Kinases in the CDK family play a significant role in the cell cycle and transcription, and thus in tumor development. The first drug targeting a CDK, a CDK4 inhibitor called palbociclib (Pfizer), was approved in February of 2015 for